SDGR — Schrödinger, Inc. stock price, charts and financials

NASDAQ·Technology·Software - Application·USA

Latest market price

29.02

-1.22-4.03%

Overview Short InterestFilings

SDGRQT67Schrödinger, Inc.·NASDAQ

Overview Short InterestFilings

29.02-4.03%

News

Down 4.0% — Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Yahoo).

Medium confidence

Loading chart...

Signal & projected range

Gap down — mean-reversionHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

VIA+0.50%$27.98 DBD-0.46%$63.20 ASAN-5.75%$9.51 DV-0.07%$13.46 KARO-2.97%$66.67 ALKT+1.97%$19.13 NCNO-1.68%$21.05 PLUS-1.02%$91.10

Snapshot

Index	-	P/E	-	EPS (ttm)	-0.74	Insider Own	13.89%	Shs Outstand	74.72M	Perf Week	52.58%

Market Cap	2.17B	Forward P/E	-	EPS next Y	-1.42	Insider Trans	-0.85%	Shs Float	57.65M	Perf Month	46.20%

Enterprise Value	1.85B	PEG	-	EPS next Q	-0.66	Inst Own	-	Short Float	19.24%	Perf Quarter	84.14%

Income	-54.00M	P/S	8.37	EPS this Y	-116.57%	Inst Trans	-	Short Ratio	9.24	Perf Half Y	137.87%

Sales	259.00M	P/B	6.59	EPS next Y	11.60%	ROA	-8.48%	Short Interest	11.09M	Perf YTD	62.30%

Book/sh	4.40	P/C	5.24	EPS next 5Y	-	ROE	-16.37%	52W High	30.41 -4.57%	Perf Year	52.50%

Cash/sh	5.54	P/FCF	-	EPS past 3/5Y	-	ROIC	-31.77%	52W Low	10.95 165.02%	Perf 3Y	-12.77%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	12.25% 18.84%	Gross Margin	56.87%	Volatility	13.51% 6.76%	Perf 5Y	-53.76%

Dividend TTM	-	EV/Sales	7.13	EPS Y/Y TTM	71.21%	Oper. Margin	-59.24%	ATR (14)	1.59	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	2.71	Sales Y/Y TTM	24.52%	Profit Margin	-20.98%	RSI (14)	77.22	Recom	2.33

Dividend Gr. 3/5Y	-	Current Ratio	2.71	EPS Q/Q	113.56%	SMA20	36.79%	Beta	1.59	Target Price	19.00

Payout	0.00%	Debt/Eq	0.30	Sales Q/Q	7.27%	SMA50	57.40%	Rel Volume	3.69	Prev Close	30.24

Employees	850	LT Debt/Eq	0.26	Earnings	Nov 04	SMA200	88.97%	Avg Volume	1.41M	Price	29.02

IPO Date	Feb 05, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	119.30% 24.80%	Net Debt/EBITDA	3.92	Volume	5,226,072	Change	-4.03%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-14-26	Reiterated	UBS	Neutral	$18 → $19
Jan-07-26	Reiterated	UBS		$18
Dec-15-25	Upgrade	B of A Securities	Neutral → Buy
Sep-29-25	Initiated	Goldman Sachs	Neutral	$27 → $19
Aug-15-25	Downgrade	Citigroup	Buy → Neutral
Nov-13-24	Reiterated	BMO Capital	Outperform	$28
Sep-23-24	Reiterated	Goldman Sachs	Neutral	$23 → $27
Aug-21-24	Reiterated	Morgan Stanley	Equal Weight	$30
Jul-02-24	Initiated	Leerink	Outperform	$29
Dec-19-22	Initiated	Goldman Sachs	Neutral	$23

Latest News· Times ET

Sep-17-26

Sep-17-2608:30AM

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Yahoo

07:15AM

Schrödinger: Company Creation Is Now The Real Drug Businessseekingalpha.com

Sep-16-26

Sep-16-2606:31AM

Schrödinger, Inc. (SDGR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com

03:56AM

Schrodinger (SDGR) Soars 12.1%: Is Further Upside Left in the Stock?zacks.com

Sep-14-26

Sep-14-2607:00AM

AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033gurufocus.com

Sep-09-26

Sep-09-2607:00AM

Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation ProgramsYahoo

Sep-07-26

Sep-07-2611:53PM

Jupiter Topco LLC Acquires Shares of 28,299 Schrodinger, Inc. $SDGRdefenseworld.net

Sep-03-26

Sep-03-2610:32AM

Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?Yahoo

Sep-01-26

Sep-01-2604:30AM

Schrödinger to Present at Morgan Stanley Global Healthcare Conferencebusinesswire.com

Aug-29-26

Aug-29-2612:11AM

BlackRock Inc. Buys New Shares in Schrodinger, Inc. $SDGRdefenseworld.net

Aug-21-26

Aug-21-2605:48AM

Schrodinger: The Software Business Is Stronger Than It LooksSeekingAlpha

Aug-17-26

Aug-17-2607:01AM

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharmazacks.com

Aug-14-26

Aug-14-2603:42PM

Schrodinger Inc (SDGR) Stock Down 4.8% -- Now Undervalued? GF Score: 73/100gurufocus.com

04:30AM

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)businesswire.com

Aug-13-26

Aug-13-2611:45PM

Critical Review: Schrodinger (NASDAQ:SDGR) versus Weave Communications (NYSE:WEAV)defenseworld.net

Company

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	259	256	208	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	111	113	75	—	—	—	—	—	—
Gross Profit	147	143	132	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	132	136	140	—	—	—	—	—	—
Research and Development	169	173	202	—	—	—	—	—	—
Other Operating Expense	-1	1	-1	—	—	—	—	—	—
Operating Income	-154	-167	-209	—	—	—	—	—	—
Interest Expense	0	0	0	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	101	65	24	—	—	—	—	—	—
Net Income Before Taxes	-53	-102	-186	—	—	—	—	—	—
Income Taxes	1	1	1	—	—	—	—	—	—
Consolidated Net Income	-54	-103	-187	—	—	—	—	—	—
Net Income From Continuing Operations	-54	-103	-187	—	—	—	—	—	—
Net Income	-54	-103	-187	—	—	—	—	—	—
EPS (Recurring)	-0.74	-1.41	-2.57	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-0.74	-1.41	-2.57	—	—	—	—	—	—
EPS (Diluted)	-0.74	-1.41	-2.57	—	—	—	—	—	—
EBITDA	-46	-96	-180	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	8.40	5.10	6.77	—	—	—	—	—	—
Gross Margin	56.76	55.86	63.46	—	—	—	—	—	—
Operating Margin	-59.46	-65.23	-100.48	—	—	—	—	—	—
Net Margin	-20.85	-40.23	-89.90	—	—	—	—	—	—
Shares Outstanding	75	73	73	—	—	—	—	—	—
Market Capitalization	2,177	1,305	1,408	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jain Rachit	EVP & CFO	Jul 16 '26	Sale	15.60	875	13,647	50,877	Jul 17
Farid Ramy	President & CEO	Apr 17 '26	Sale	12.21	43,000	524,944	330,824	Apr 17
Farid Ramy	President & CEO	Apr 17 '26	Option Exercise	3.07	117,527	360,808	405,351	Apr 17
Farid Ramy	President & CEO	Apr 16 '26	Option Exercise	3.07	43,000	132,010	117,527	Apr 17
Farid Ramy	President & CEO	Apr 16 '26	Sale	12.33	43,000	530,233	330,824	Apr 17
Jain Rachit	EVP & CFO	Apr 16 '26	Sale	12.75	844	10,758	51,752	Apr 17
Herman Jenny	CAO	Mar 06 '26	Sale	12.84	608	7,808	34,804	Mar 06
Tran Yvonne	EVP, CLO & CPO	Mar 05 '26	Sale	12.89	1,094	14,107	52,683	Mar 06
Herman Jenny	CAO	Mar 05 '26	Sale	12.85	775	9,956	35,412	Mar 06
Jain Rachit	EVP & CFO	Mar 05 '26	Sale	12.90	1,631	21,033	52,596	Mar 06
Farid Ramy	President & CEO	Mar 05 '26	Sale	12.91	3,661	47,249	330,824	Mar 06
Akinsanya Karen	See Remarks	Mar 05 '26	Sale	12.90	1,366	17,625	69,956	Mar 06
Lorton Kenneth Patrick	EVP, CTO & COO, Software	Mar 05 '26	Sale	12.90	1,222	15,761	89,241	Mar 06
Abel Robert Lorne	See Remarks	Mar 04 '26	Sale	12.81	1,300	16,653	55,897	Mar 06
Tran Yvonne	EVP, CLO & CPO	Feb 10 '26	Sale	13.80	776	10,705	22,859	Feb 12

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.